

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/263889 A3

(51) International Patent Classification:

A61K 31/416 (2006.01) C07D 471/22 (2006.01)
A61K 31/4155 (2006.01) A61P 35/00 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2024/034979

(22) International Filing Date:

21 June 2024 (21.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/510,056	23 June 2023 (23.06.2023)	US
63/588,518	06 October 2023 (06.10.2023)	US
63/575,674	06 April 2024 (06.04.2024)	US
63/659,580	13 June 2024 (13.06.2024)	US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.**

[US/US]; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US).

(72) Inventors: **CUI, Jingrong Jean**; 3525 John Hopkins Court,

Suite 100, San Diego, California 92121 (US). **JIANG,**


Ping; 3525 John Hopkins Court, Suite 100, San Diego, Cal-
ifornia 92121 (US). **DENG, Wei**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **ZHAI, Day-**
ong; 3525 John Hopkins Court, Suite 100, San Diego, Cal-
ifornia 92121 (US). **LI, Danan**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US).

(74) Agent: **LEWALLEN, Daniel M.**; BARNES & THORN-
BURG LLP, 11 S. Meridian Street, Indianapolis, Indiana
46204 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS



(57) Abstract: The present disclosure relates to methods and compositions for treating cancer with a macrocyclic indazole compound in combination with at least one other cancer therapeutic, such as a Bcl-2 inhibitor, a FLT3 inhibitor, a KRAS inhibitor, an ALK inhibitor, a PARP inhibitor, an EGFR inhibitor, a chemotherapy, and the like.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

15 May 2025 (15.05.2025)